Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Sep 13;52(5):619–624. doi: 10.1007/s11055-022-01286-4

Postcovid Syndrome – The New Reality

M A Khoreva 1,✉
PMCID: PMC9468516  PMID: 36119648

Abstract

The second year of the COVID-19 pandemic has demonstrated the need for detection and assessment of the long-term consequences SARS-CoV-2 infection, including adequate cognitive functioning. This review addresses our current understanding of the direct and indirect mechanisms of nervous system infection in COVID-19, paying special attention to cause-effect relationships between SARS-CoV-2 infection and long-term neuropsychological disorders. Understanding the pathogenesis of neurological impairments in COVID-19 is important for studies of the long-term sequelae of the disease and for identifying preventive and therapeutic possibilities in relation to brain damage. Further studies of nervous system lesions in COVID-19 are clearly needed to expand existing knowledge. Early initiation of therapeutic measures for emerging disorders will probably have decisive importance for improving quality of life for many COVID-19 survivors.

Keywords: COVID-19, long-term sequelae, cognitive disorders

Footnotes

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 10, Iss. 1, pp. 131–137, October, 2021.

References

  • 1.A. Yassin, M. Nawaiseh, A. Shaban, et al., “Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis,” BMC Neurol., 21, No. 1, 138 (2021), 10.1186/s12883-021-02161-4. [DOI] [PMC free article] [PubMed]
  • 2.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542–2020. doi: 10.1183/23120541.00542-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Akbarialiabad H, Taghrir MH, Abdollahi A, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;28:1–24. doi: 10.1007/s15010-021-01666-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sigfrid L, Drake TM, Pauley E, et al. Long covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Regional Health Eur. 2021;8:100186. doi: 10.1016/j.lanepe.2021.100186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. doi: 10.1001/jama.2020.12603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. doi: 10.1038/s41586-021-03553-9. [DOI] [PubMed] [Google Scholar]
  • 8.S. H. Chou, E. Beghi, R. Helbok, et al., “Global incidence of neurological manifestations among patients hospitalized with COVID-19 – A report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium,” JAMA Netw. Open, 4, No. 5, e2112131 (2021), 10.1001/jamanetworkopen.2021.12131. [DOI] [PMC free article] [PubMed]
  • 9.Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382(23):2268–2270. doi: 10.1056/NEJMc2008597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. doi: 10.1016/S2215-0366(20)30203-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhou H, Lu S, Chen J, et al. The landscape of cognitive function in recovered COVID-19 patients. J. Psychiatr. Res. 2020;129:98–102. doi: 10.1016/j.jpsychires.2020.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.H. Ali Awan, M. Najmuddin Diwan, A. Aamir, et al., “SARS-CoV-2 and the brain: What do we know about the causality of Cognitive COVID?” J. Clin. Med., 10, No. 15, 3441 (2021), 10.3390/jcm10153441. [DOI] [PMC free article] [PubMed]
  • 13.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Taquet M, Geddes JR, Husain M, et al. 6-Month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–427. doi: 10.1016/S2215-0366(21)00084-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jaywant A, Vanderlind WM, Alexopoulos GS, et al. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. 2021;15:1–6. doi: 10.1038/s41386-021-00978-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hampshire A, Trender W, Chamberlain S, et al. Cognitive deficits in people who have recovered from COVID-19. EClinical-Medicine. 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.M. S. Woo, J. Malsy, J. Pöttgen, et al., “Frequent neurocognitive deficits after recovery from mild COVID-19,” Brain Commun., 2, No. 2, fcaa205 (2020), 10.1093/braincomms/fcaa205. [DOI] [PMC free article] [PubMed]
  • 18.Dubey S, Biswas P, Ghosh R, et al. Psychosocial impact of COVID-19. Diabetes Metab. Syndr. 2020;14(5):779–788. doi: 10.1016/j.dsx.2020.05.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.S. N. Mosolov, “Mental health problems in the COVID-19 pandemic,” Zh. Nevrol. Psikhiatr., 120, No. 5, 7–15 (2020), 10.17116/jnevro20201200517. [DOI] [PubMed]
  • 20.Cagnin A, Di Lorenzo R, Marra C, et al. Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia. Front. Psychiatry. 2020;11:578015. doi: 10.3389/fpsyt.2020.578015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cohen G, Russo MJ, Campos JA, Allegri RF. COVID-19 epidemic in Argentina: Worsening of behavioral symptoms in elderly subjects with dementia living in the community. Front. Psychiatry. 2020;11:866. doi: 10.3389/fpsyt.2020.00866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Brown EE, Kumar S, Rajji TK, et al. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer’s disease and related dementias. Am. J. Clin. Geriatr. Psychiatry. 2020;28(7):712–721. doi: 10.1016/j.jagp.2020.04.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.K. Ritchie, D. Chan, and T. Watermeyer, “The cognitive consequences of the COVID-19 epidemic: collateral damage?” Brain Commun., 2, No. 2, fcaa069 (2020), 10.1093/braincomms/fcaa069. [DOI] [PMC free article] [PubMed]
  • 25.Cagnin A, Di Lorenzo R, Marra C, et al. Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia. Front. Psychiatry. 2020;11:578015. doi: 10.3389/fpsyt.2020.578015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.A. Ramani, L. Müller, P. N. Ostermann, et al., “SARS-CoV-2 targets neurons of 3D human brain organoids,” EMBO J., 39, No. 20, e106230 (2020), 10.15252/embj.2020106230. [DOI] [PMC free article] [PubMed]
  • 27.Chekol Abebe E, Mengie Ayele T, Tilahun Muche Z, Asmamaw Dejenie T. Neuropilin 1: A novel entry factor for SARS-CoV-2 infection and a potential therapeutic target. Biologics. 2021;15:143–152. doi: 10.2147/BTT.S307352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.M. A. Erickson, E. M. Rhea, R. C. Knopp, and W. A. Banks, “Interactions of SARS-CoV-2 with the blood–brain barrier,” Int. J. Mol. Sci., 22, No. 5, 2681 (2021), 10.3390/ijms22052681. [DOI] [PMC free article] [PubMed]
  • 29.Jha NK, Ojha S, Jha SK, et al. Evidence of coronavirus (CoV) pathogenesis and emerging pathogen sars-cov-2 in the nervous system: A review on neurological impairments and manifestations. J. Mol. Neurosci. 2021;19:1–18. doi: 10.1007/s12031-020-01767-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.A. Al-Ramadan, O. Rabab’h, J. Shah, and A. Gharaibeh, “Acute and post-acute neurological complications of COVID-19,” Neurol. Int., 13, No. 1, 102–119 (2021), 10.3390/neurolint13010010. [DOI] [PMC free article] [PubMed]
  • 31.E. Song, C. Zhang, B. Israelow, et al., “Neuroinvasion of SARSCoV-2 in human and mouse brain,” J. Exp. Med., 218, No. 3, e20202135 (2021), 10.1084/jem.20202135. [DOI] [PMC free article] [PubMed]
  • 32.Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Mov. Disord. 2020;35(5):716–720. doi: 10.1002/mds.28084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lu Y, Li X, Geng D, et al. Cerebral Micro-structural changes in COVID-19 patients – An MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484. doi: 10.1016/j.eclinm.2020.100484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020;92(6):552–555. doi: 10.1002/jmv.25728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yong SJ. Persistent brainstem dysfunction in long-COVID: A hypothesis. ACS Chem. Neurosci. 2021;12(4):573–580. doi: 10.1021/acschemneuro.0c00793. [DOI] [PubMed] [Google Scholar]
  • 36.Mukaetova-Ladinska EB, Kronenberg G, Raha-Chowdhury R. COVID-19 and neurocognitive disorders. Curr. Opin. Psychiatry. 2021;34(2):149–156. doi: 10.1097/YCO.0000000000000687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.D. Lahiri and A. Ardila, “COVID-19 pandemic: A neurological perspective,” Cureus, 12, No. 4, e7889 (2020), 10.7759/cureus.7889. [DOI] [PMC free article] [PubMed]
  • 38.Beishon L, Panerai RB. The neurovascular unit in dementia: An opinion on current research and future directions. Front. Aging Neurosci. 2021;13:721937. doi: 10.3389/fnagi.2021.721937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.S. Miners, P. G. Kehoe, and S. Love, “Cognitive impact of COVID-19: looking beyond the short term,” Alzheimers Res. Ther., 12, No. 1, 170 (2020), 10.1186/s13195-020-00744-w. [DOI] [PMC free article] [PubMed]
  • 40.C. Sasannejad, E. W. Ely, and S. Lahiri, “Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms,” Crit. Care, 23, No. 1, 352 (2019), 10.1186/s13054-019-2626-z. [DOI] [PMC free article] [PubMed]
  • 41.Ardila A, Lahiri D. Executive dysfunction in COVID-19 patients. Diabetes Metab. Syndr. 2020;14(5):1377–1378. doi: 10.1016/j.dsx.2020.07.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Honarmand K, Lalli RS, Priestap F, et al. Natural history of cognitive impairment in critical illness survivors. A systematic review. Am. J. Respir. Crit. Care Med. 2020;202(2):193–201. doi: 10.1164/rccm.201904-0816CI. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N. Engl. J. Med. 2013;369:1306–1316. doi: 10.1056/NEJMoa1301372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27. doi: 10.1016/j.cell.2020.08.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.De Erausquin GA, Snyder H, Carrillo M, et al. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement (NY) 2021;17(6):1056–1065. doi: 10.1002/alz.12255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.N. Moghimi, M. Di Napoli, J. Biller, et al., “The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection,” Curr. Neurol. Neurosci. Rep., 21, No. 9, 44 (2021), 10.1007/s11910-021-01130-1. [DOI] [PMC free article] [PubMed]
  • 47.O. A. Gomazkov, “Corexin: Molecular mechanisms and targets for neuroprotective Activity,” Zh. Nevrol. Psikhiatr., 115, No. 8, 99–104 (2015), 10.17116/jnevro20151158199-104. [DOI] [PubMed]
  • 48.Yakovlev AA, Lyzhin AA, Khaspekov LG, et al. Peptide drug cortexin inhibits brain caspase-8. Biomed. Khim. 2017;63(1):27–31. doi: 10.18097/PBMC20176301027. [DOI] [PubMed] [Google Scholar]
  • 49.V. G. Pinelis, T. P. Storozhevykh, E. G. Sorokina, et al., “Effects of Cortexin on the survival of cultured brain neurons exposed to glutamate toxicity or deprived of growth factors,” in: Peptide Neuroprotection. A Collection of Scientifi c Reports, M. M. D’yakonov and A. A. Kamenskii (eds.), Nauka, St. Petersburg (2009).
  • 50.S. I. Shram and A. V. Baibak, “Cytoprotective action of Cortexin and retinalamine in models of necrotic neuron death induced by oxidative stress,” in: Peptide Neuroprotection. A Collection of Scientifi c Reports, M. M. D’yakonov and A. A. Kamenskii (eds.), Nauka, St. Petersburg (2009).
  • 51.Yakovlev AA, Gulyaeva NV. Molecular partners of Cortexin in the brain. Neirokhimiya. 2017;33(1):91–96. doi: 10.7868/s1027813316040166. [DOI] [Google Scholar]
  • 52.Stepanichev MY, Onufriev MV, Lazareva NA, et al. Effects of the formulation Cortexin on free radical oxidation and infl ammatory processes in rats with normal and accelerated aging. Neirokhimiya. 2018;35(2):1–12. doi: 10.7868/s1027813318020127. [DOI] [Google Scholar]
  • 53.N. V. Gulyaeva, “Molecular mechanisms of action of formulations containing brain peptides: Cortexin,” Zh. Nevrol. Psikhiatr., 118, No. 10, 93–96 (2018), 10.17116/jnevro201811810193. [DOI] [PubMed]

Articles from Neuroscience and Behavioral Physiology are provided here courtesy of Nature Publishing Group

RESOURCES